Number of pages: 100 | Report Format: PDF | Published date: May 25, 2023
Historical Years – 2021 | Base Year – 2022 | Forecasted Years – 2023 to 2031
Report Attribute |
Details |
CAGR |
4.5% |
Base Year For Estimation |
2022 |
Forecast Period |
2023 to 2031 |
Historical Year |
2021 |
Segments Covered |
Drug Class, Indication, Distribution Channel, and Region |
Regional Scope |
North America, Europe, Asia Pacific, Latin America, and the Middle East & Africa |
According to the deep-dive market assessment study by Growth Plus Reports, the global calcium homeostasis drugs market is expected to register a revenue CAGR of 4.5% during the forecast period.
Calcium Homeostasis Drugs Market Fundamentals
A uniform concentration of calcium ions in the extracellular fluid is referred to as calcium homeostasis. For bone formation, blood clotting, muscular contraction, nerve conduction, excitation-secretion coupling, and cardiac contractility, maintaining a steady plasma [Ca2+] is crucial. Serum calcium, serum phosphate, 1,25-dihydroxyvitamin D-3, and parathyroid hormone (PTH) are the four essential factors in the complicated process of calcium homeostasis. More than 99% of the body's total calcium is kept in bones as phosphate and hydroxide salts, mostly as hydroxyapatite.Very little calcium is typically accessible for exchange in the serum. Since 99% of the calcium in the human body is found in bone, it plays a significant role as a calcium storage area. The parathyroid hormone controls the release of calcium from bones. Calcium is encouraged to be incorporated into bones by calcitonin. Low calcium consumption might increase the chance of developing osteoporosis. A greater bone balance lowers the risk of osteoporosis.
Hypercalcemia and hypocalcemia are two conditions that can result from calcium homeostasis; both of these conditions have the potential to be dangerous and even fatal. Treatment for either hypercalcemia or hypocalcemia focuses on treating the underlying condition that often disrupts calcium homeostasis. In severe cases, calciuresis or calcium supplementation might be used to restore calcium levels to normal. For milder instances, supportive treatments that improve the functioning of the parathyroid, thyroid, kidney, gut, and bone will enable the body to make up for an excess or deficiency of calcium and use internal hormonal regulatory mechanisms to bring the calcium levels back to balance. The most frequent cause of rapidly progressing hypercalcemia is a malignancy. Thus, patients should undergo laboratory tests to check for blood malignancies such as multiple myeloma, lymphoma, and leukemia and radiographic evaluations for lung, breast, and kidney masses.
Calcium Homeostasis Drugs Market Dynamics
The prevalence of calcium homeostasis is mostly due to osteoporosis disease being prevalent in the elderly patient pool, postmenopausal women, patients with parathyroid hormone disorders, and males with a high risk of fractures. The prevalence of osteoporosis was 34.8%, with the highest diagnosis rate in South Korea at 22.1%, according to a research titled "Spread and experience of diagnosing osteoporosis in postmenopausal women over the age of 50: Focus on social issues" that was released in March 2021. Another significant driver of the market's expansion is the rise in the number of young individuals worldwide that are particularly susceptible to bone growth. For instance, the International Osteoporosis Foundation estimates that 1 in 5 men and 1 in 3 women over 50 may sustain an osteoporosis fracture over their remaining lifetimes in 2020.
Globally, there has been a striking rise in the awareness of osteoporosis, a significant trend in osteoporosis medicine. This awareness is primarily due to the different programs and efforts that both public and commercial organizations are running. For instance, the International Osteoporosis Foundation is a company that deals with osteoporosis. At the same time, National Osteoporosis Awareness and Prevention Month is observed in May in the United States to raise awareness of the consequences and effects of osteoporosis by holding various activities such as conferences, seminars, and workshops.
The growing prevalence of secondary hypoparathyroidism due to an expanded patient population for dialysis is another important and major factor driving the market's expansion. Renal difficulties are becoming more common among people around the globe, bringing attention to the concurrent illnesses that accompany them. Secondary hyperparathyroidism is most likely to occur in people with end-stage renal disease (ESRD) and chronic kidney disease (CKD). One important sign of the growing patient base for calcium homeostasis is the dramatic increase in the incidence of chronic illnesses like diabetes. Diabetes is a significant contributor to the development of nephropathy in the U.S. The prevalence of diabetes in the U.S. is above 9.4% since nephropathy affects about 40% of diabetic patients.
Calcium Homeostasis Drugs Market Ecosystem
The global calcium homeostasis drugs market is analyzed from the following perspectives: drug class, indication, distribution channel, and region.
Calcium Homeostasis Drugs Market by Drug Class
Based on the drug class, the global calcium homeostasis drugs market is segmented into calcium metabolism modifiers, parathyroid hormone analogs, calcimimetics, vitamin D analogs, and others.
The parathyroid hormone analogs showed significant growth during the forecast period. The segment for parathyroid hormone analogues is anticipated to grow in response to the rising prevalence of osteoporosis. Low bone mass and deteriorating bone tissue are symptoms of the condition osteoporosis, which increases the risk of fracture. Osteoporosis affects over 1.4 million Canadians, mostly postmenopausal women and the elderly, according to the International Osteoporosis Foundation. As a daily subcutaneous injection, the parathyroid hormone, which the body naturally produces to control calcium levels, helps patients with osteoporosis lower their risk of bone breakage. Therefore, the rise in osteoporosis will impact the growth of the parathyroid hormone analog segment.
Calcium Homeostasis Drugs Market by Indication
Based on the indication, the global calcium homeostasis drugs market is segmented into hypocalcemia, hypercalcemia, hyperparathyroidism, osteoporosis, and others.
The hypercalcemia segment is likely to show significant growth during the forecasted period. In the general population, hypercalcemia affects 1% to 2% of people. 90% of instances of hypercalcemia are caused by primary hyperparathyroidism and hypercalcemia linked to cancer. Primary hyperparathyroidism affects 0.2% to 0.8% of the general population, and its frequency rises with age. Hypercalcemia is linked to 2% of all malignancies overall, while among children and adolescents, the prevalence ranges from 0.4% to 1.3%. To increase patient compliance and make treatment easier for them, manufacturers are investing in research and development initiatives to create alternative pharmacological treatments for surgery. Manufacturers' primary strategies to boost their income include new product launches through intensive R&D, mergers, acquisitions, partnerships, and product portfolio enhancement. By using these techniques, businesses can increase their regional presence and product offerings.
Calcium Homeostasis Drugs Market by Distribution Channel
Based on the distribution channel, the globalcalcium homeostasis drugs market is segmented into hospital pharmacies, retail pharmacies, and online pharmacies.
Due to the growing number of facilities and patients' ease of access, hospitals and retail pharmacies are anticipated to have the largest market share among all distribution channels. Additionally, one of the key reasons fueling the market's expansion throughout the projection period is the speedy delivery of drugs. As the prevalence of hypoparathyroidism, osteoporosis, hypocalcemia, and hypercalcemia rises, there is a growing need for medication to be more easily accessible and readily available so that the illness may be treated as quickly as feasible. As a result, patients may receive their medications from hospitals and retail outlets more quickly, which expands the market for treatments that treat calcium homeostasis.
Calcium Homeostasis Drugs Market by Region
Based on the region, the global calcium homeostasis drugs market is segmented into North America, Europe, Asia Pacific, Latin America, and the Middle East & America.
Throughout the forecast period, North America is anticipated to lead the calcium homeostasis drugs market. The existence of major companies, the high incidence of osteoporosis, patients with secondary hyperparathyroidism in the region, the well-developed healthcare infrastructure, and the accessibility of prescription drugs all contribute to the market expansion. Due to the country's expanding adult population, the number of patients, and a number of cooperative initiatives started by big businesses to enhance their skills and assure higher medical standards, the United States has the highest market share. For instance, the National Osteoporosis Foundation (NOF) reports that more than 10 million Americans have received an osteoporosis diagnosis since 2020. This condition is particularly prevalent among menopausal women. Consequently, the rising prevalence of menopause among women is expected to be a significant growth factor contributing to the regional drug market.
The Asia Pacific region showed the fastest growth during the forecast period. One of the markets for calcium homeostasis drugs with the highest growth is India. Osteoporosis, which causes changed bone structure and reduced bone density, is more common among women in India. According to a study conducted in small groups around the country on the incidence of this disease among women, about 50 million of India's 230 million people were women over the age of 50 in 2021. As a result, osteoporosis poses a serious public health risk to Indian women. Low calcium intakes with widespread vitamin D insufficiency, extended longevity, sex inequality, early menopause, familial susceptibility, a lack of diagnostic tools, and a lack of knowledge of bone health have all been linked to the disease's high incidence.
Calcium Homeostasis Drugs Market Competitive Landscape
Some of the prominent market players in the global calcium homeostasis drugs market include,
Calcium Homeostasis Drugs Market Strategic Development
A uniform concentration of calcium ions in the extracellular fluid is referred to as calcium homeostasis.
Some major global calcium homeostasis drugs market players are Mylan Pharmaceuticals Inc., AbbVie, Inc., and F. Hoffman-La Roche.
The hypercalcemia segment showed significant growth during the forecast period.
A key trend for the market to expand during the projection period is the involvement of leading market participants in developing novel therapeutic approaches to meet patients' unmet requirements.
The North America region is dominating the global calcium homeostasis drugs market.
*Insights on financial performance are subject to the availability of information in the public domain